SEnIORIT - Escola Superior de Tecnologia da Saúde de Coimbra

More documents

Recommendations

Info

Huge success for 2´nd International suPAR Symposium in Copenhagen Denmark, March 31, 2011 From left to right: Dr Maria Lönnkvist, Karolinska University Hospital Solna, Sweden, Laboratory Research Director Jesper Eugen-Olsen, Hvidovre Hospital, Copenhagen, and Professor Marcus Schultz, Academic University Center, Amsterdam. Broad recognition was given and several promising insights were shared, when numerous clinicians and scientists were gathered in Copenhagen to discuss the new health marker suPARnostic®. Nearly 100 medical professionals attended the 2nd International suPAR Symposium in early March, to present and discuss clinical study findings. A strong interest in usage of the new biomarker in both critical care settings as well as in the general population is apparent, and expectations are high to this unique new tool in clinical decision making. 20 Bioanalyytikko 2/2011 Background Almost 100 delegates met at “The 2’nd International suPAR Symposium” in Copenhagen in March 2011. Approximately 25 high level presentations, with sole focus on the new biomarker suPAR, were presented and discussed by a variety of international researchers representing, among others, such important institutions as Karolinska Institutet, Stockholm, Rigshospitalet University Hospital, Copenhagen, Erasme University Hospital, Brussels, Achen University Hospital, Germany, Institute of Molecular Oncology (IFOM- IEO), Milan, and Academic Medi- cal Center, University of Amsterdam. The symposium was hosted by Jesper Eugen-Olsen, Ph.D., Laboratory Research Director, Clinical Research Centre, Hvidovre University Hospital, Copenhagen. The Danish developed biomarker, suPARnostic®, is already well integrated in several high level clinical research settings in a number of European countries. The marker detects inflammation and hence immune system activation, and has mainly proved its value in the hospital acute care setting, however recent studies document the biomarkers capabilities of also supporting health improvement in the general population.
The Symposium Outcome The symposium presentations emphasized the strong prognostic power of suPAR in the critical care setting and a range of application areas were detailed and discussed. "suPAR is an important bio marker in especially critically ill patients. Maybe one should combine it with other markers or scores used today and then use it as a combined marker to decide on therapy" states Professor Marcus Schultz, MD, Ph.D., Head of ICU at Academic University Centre, Amsterdam. Ove Andersen, MD, Ph.D., Head of Clinical Research Centre, Hvidovre University Hospital, Copenhagen, says that "Biomarkers like suPAR or other biomarkers in combination will help us triage the patients who need more care when admitted to hospital". Jyrki Tenhunen, MD, Ph.D., Head of ICU, Tampere University Hospital, Finland supplements by commenting that “What we really seem to have in our hands is a method for early risk recognition, enabling us to choose the patients for further investigations and early treatment interventions.” It has been clearly demonstrated that moderately elevated suPAR levels in the general population provides important and tangible information with respect to risk factors and long term health prognosis for assumed healthy persons. Nicolai Sidenius, Ph.D., IFOM- IEO, Milan says that "I assume that the major use of suPAR will be in the big diseases where there is also a market of even marginal improvement in diagnosis and prognosis. In particular in cardio vascular disease there is a great future". This statement links closely with the MONICA cohort findings published in Journal of Internal Medicine on 28 May 2010. Here it was demonstrated that elevated baseline suPAR level was associated with a significant increased risk of developing cancer, cardiovascular diseases (CVD), type- 2 diabetes (T2D) and mortality. Dr. Eugen-Olsen says “Our data suggest that suPAR may, in addition to patient triaging, be used in individual risk assessment. We have recently found that suPAR is influenced by lifestyle, e.g. it is higher in smokers. However, what is really interesting is that it is those smokers with the highest suPAR levels that have the highest risk of developing diseases, such as lung cancer.” About ViroGates A/S ViroGates is an international Medtech company headquartered in Copenhagen, Denmark. ViroGates develops and distributes prognostic products for healthcare management with a single goal in mind: To identify risk patients early and improve or save the lives. The novel Viro- Gates method, called suPARnostic®, involves the measurement of the concentration of a protein found in every individual (known as soluble urokinase Plasminogen Activator Receptor or suPAR). ViroGates has launched suPARnostic® in several countries in Europe, Africa and Asia and is preparing further suPARnostic® prod- From left to right: MD Ove Andersen, Head of Clinical Research Centre, Hvidovre Hospital, Copenhagen, Laboratory Research Director Jesper Eugen-Olsen, Hvidovre Hospital, Copenhagen, MD Margaretha Persson, Skåne University Hospital, Sweden, and MD Jyrki Tenhunen, Head of ICU, Tampere University Hospital, Finland. Bioanalyytikko 2/2011 21
Page 1 and 2: www.bioanalyytikkoliitto.fi 2/2011
Page 3 and 4: Lehden julkaisija: Suomen Bioanalyy
Page 5 and 6: Aktuellt - trevliga och mindre trev
Page 7 and 8: Våren är redan långt gången och
Page 9 and 10: Bioanalyytikkoja kulttuuripääkaup
Page 11 and 12: Valmistuttuani bioanalyytikoksi 200
Page 13 and 14: tä, vastuuhenkilöistä, työohjei
Page 15 and 16: Opettajavaihdossa Coimbrassa, opisk
Page 17 and 18: ESTES Coimbran opiskelijoita koulul
Page 19: sanottua, kunhan vain uskaltaa kysy
Page 23 and 24: Laboratoriolääketiede ja näyttel
Page 25 and 26: PERJANTAI 7.10.2011 Lisätietoja: S
Page 27 and 28: mm. laadittaessa osaamisprofiileja
Page 29 and 30: Tiedonkulussa koettiin erityisesti
Page 31 and 32: miskierrokset järjestetään vasta
Page 33 and 34: lisäksi kaksi ensimmäistä vuotta
Page 35 and 36: - Harrasta mieluisia asioita, kultt
Page 37 and 38: RYHMÄHENKIVAKUUTUS Virka- ja työe
Page 39 and 40: TÄRKEITÄ PÄIVÄMÄÄRIÄ SUOMEN
Page 41 and 42: Anja valmistui ensimmäiseltä labo
Page 43 and 44: Pohjois-Karjalan Bioanalyytikot kok
Page 45 and 46: Suomen Bioanalyytikkoliitto ry, Fin
Page 47 and 48: Bioanalyytikko 2/2011 47

SEnIORIT - Escola Superior de Tecnologia da Saúde de Coimbra

Create successful ePaper yourself

Delete template?

Save as template?